Repligen (RGEN) News Today $138.90 +10.41 (+8.10%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period KBC Group NV Lowers Stock Holdings in Repligen Co. (NASDAQ:RGEN)KBC Group NV cut its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 64.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,969 shares of the biotechnology company's stock after selling 5,483 sharesNovember 20 at 3:46 AM | marketbeat.comParnassus Investments LLC Sells 7,060 Shares of Repligen Co. (NASDAQ:RGEN)Parnassus Investments LLC decreased its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 1.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 381,471 shares of the biotechnology coNovember 19 at 9:14 AM | marketbeat.comFirst Turn Management LLC Makes New $13.20 Million Investment in Repligen Co. (NASDAQ:RGEN)First Turn Management LLC purchased a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 88,714 shares of the biotechnology company's stock, valued at approximately $13,202,00November 19 at 6:08 AM | marketbeat.comLMR Partners LLP Invests $3.60 Million in Repligen Co. (NASDAQ:RGEN)LMR Partners LLP purchased a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 24,167 shares of the biotechnology company's stock,November 19 at 5:36 AM | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Purchased by Thrivent Financial for LutheransThrivent Financial for Lutherans increased its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 6.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 638,602 shares of the biNovember 18 at 5:40 AM | marketbeat.comRepligen (NASDAQ:RGEN) Stock Price Down 4.8% - Here's WhyNovember 17, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on Repligen FY2024 EarningsNovember 17, 2024 | americanbankingnews.comWolfe Research Initiates Coverage of Repligen (RGEN) with Peer Perform RecommendationNovember 15, 2024 | msn.comRepligen (NASDAQ:RGEN) Shares Down 4.8% - Should You Sell?Repligen (NASDAQ:RGEN) Stock Price Down 4.8% - Here's WhyNovember 15, 2024 | marketbeat.comRepligen’s Robust Growth and Market Position Drive Buy Rating with $200 Price TargetNovember 15, 2024 | markets.businessinsider.comLeerink Partnrs Comments on Repligen FY2024 EarningsRepligen Co. (NASDAQ:RGEN - Free Report) - Stock analysts at Leerink Partnrs issued their FY2024 EPS estimates for Repligen in a research note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst P. Souda forecasts that the biotechnology company will earn $1.55 per share for theNovember 15, 2024 | marketbeat.comAigen Investment Management LP Trims Stock Position in Repligen Co. (NASDAQ:RGEN)Aigen Investment Management LP cut its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 55.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,275 shares of the biotechnology company's stockNovember 15, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 30.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 120,991 shares of the biotechnology compaNovember 15, 2024 | marketbeat.comSivik Global Healthcare LLC Has $3.72 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)Sivik Global Healthcare LLC increased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 66.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,000 shares of the biotechnology company's stockNovember 14, 2024 | marketbeat.comRepligen (NASDAQ:RGEN) Earns Peer Perform Rating from Analysts at Wolfe ResearchWolfe Research began coverage on Repligen in a research note on Thursday. They issued a "peer perform" rating on the stock.November 14, 2024 | marketbeat.comRepligen’s Strong Q3 and Strategic MovesNovember 14, 2024 | markets.businessinsider.comRepligen Corporation (NASDAQ:RGEN) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comRepligen (RGEN) Receives a Hold from Benchmark Co.November 14, 2024 | markets.businessinsider.comRepligen (NASDAQ:RGEN) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPSRepligen (NASDAQ:RGEN - Get Free Report) posted its quarterly earnings data on Tuesday. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. Repligen's quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.23 earnings per share.November 13, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Position Boosted by Geneva Capital Management LLCGeneva Capital Management LLC grew its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 8.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 138,677 shares of the biotechnology company'sNovember 13, 2024 | marketbeat.comVersor Investments LP Takes $893,000 Position in Repligen Co. (NASDAQ:RGEN)Versor Investments LP purchased a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,001 shares of the biotechnology compNovember 13, 2024 | marketbeat.comRepligen Corp (RGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...November 13, 2024 | finance.yahoo.comRepligen Beats on EPS and Sales in Q3November 12, 2024 | fool.comRepligen Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | markets.businessinsider.comRepligen Reports Strong Q3 2024 with Revenue GrowthNovember 12, 2024 | markets.businessinsider.comRepligen Corporation (RGEN) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comRepligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term GrowthNovember 12, 2024 | benzinga.comRepligen Stock Soars 10% on Record Growth and Bold MovesNovember 12, 2024 | gurufocus.comRepligen (NASDAQ:RGEN) Updates FY 2024 Earnings GuidanceRepligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance. The company provided EPS guidance of 1.500-1.580 for the period, compared to the consensus estimate of 1.430.November 12, 2024 | marketbeat.comRepligen (NASDAQ:RGEN) Updates FY24 Earnings GuidanceRepligen (NASDAQ:RGEN) updated its FY24 earnings guidance. The company provided EPS guidance of $1.50-1.58 for the period, compared to the consensus estimate of $1.44. The company also issued revenue guidance of $630-639 millionillion, compared to the consensus estimate of $629.61 millionillion.November 12, 2024 | marketbeat.comRepligen Corporation's Earnings Preview: Expensive With Mixed Growth ProspectsNovember 12, 2024 | seekingalpha.comWCM Investment Management LLC Buys 32,126 Shares of Repligen Co. (NASDAQ:RGEN)WCM Investment Management LLC lifted its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 47.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 99,158 shares of the biotechnology company's stock after purchasing an aNovember 12, 2024 | marketbeat.comRepligen Corp (RGEN) Q3 2024: Everything You Need to Know Ahead of EarningsNovember 11, 2024 | gurufocus.comRepligen Co. (NASDAQ:RGEN) Shares Purchased by TimesSquare Capital Management LLCTimesSquare Capital Management LLC raised its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 14.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 275,627 sharesNovember 10, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Position Reduced by Van ECK Associates CorpVan ECK Associates Corp lowered its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 13.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 39,160 shares of the biotechnology company's stock after selling 6,025 shares during the period. Van ECK Associates CorNovember 8, 2024 | marketbeat.comUS Bancorp DE Cuts Stock Holdings in Repligen Co. (NASDAQ:RGEN)US Bancorp DE lessened its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 34.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,032 shares of the biotechnology company's stock after selling 5,26November 8, 2024 | marketbeat.comRepligen (RGEN) Scheduled to Post Earnings on TuesdayRepligen (NASDAQ:RGEN) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643456)November 5, 2024 | marketbeat.comRepligen Corporation to Present at Upcoming Investor ConferencesNovember 5, 2024 | globenewswire.comImpax Asset Management Group plc Sells 68,709 Shares of Repligen Co. (NASDAQ:RGEN)Impax Asset Management Group plc lowered its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 6.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,058,169 shares of the biotechnology company's stock after selling 68,709 shares during the quarter. ImpaxNovember 5, 2024 | marketbeat.comNew York State Common Retirement Fund Grows Stock Holdings in Repligen Co. (NASDAQ:RGEN)New York State Common Retirement Fund lifted its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 14.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 567,044 shares of the biotechnology company's stock after buying anNovember 2, 2024 | marketbeat.comConestoga Capital Advisors LLC Sells 6,167 Shares of Repligen Co. (NASDAQ:RGEN)Conestoga Capital Advisors LLC decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 0.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 940,710 shares of the biotechnology company's stock after selling 6,167 shares during the peNovember 1, 2024 | marketbeat.comRepligen to Report Third Quarter 2024 Financial ResultsOctober 31, 2024 | markets.businessinsider.comRepligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have given aOctober 29, 2024 | marketbeat.comRaymond James & Associates Increases Stock Holdings in Repligen Co. (NASDAQ:RGEN)Raymond James & Associates raised its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 49.3% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 82,277 shares of the biotechnology company's stock after purchasing an additional 27,158October 28, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Has $37.81 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)Allspring Global Investments Holdings LLC reduced its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 8.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 254,054 shares of the biotechnology company's stock after selling 24,164 shares during the period.October 23, 2024 | marketbeat.comRepligen (NASDAQ:RGEN) Shares Gap Down - Here's What HappenedRepligen (NASDAQ:RGEN) Shares Gap Down - What's Next?October 22, 2024 | marketbeat.comRepligen (NASDAQ:RGEN) Shares Gap Up - Here's WhyRepligen (NASDAQ:RGEN) Shares Gap Up - Should You Buy?October 17, 2024 | marketbeat.comRepligen Corporation (RGEN)October 17, 2024 | finance.yahoo.comRepligen (NASDAQ:RGEN) Stock Price Down 2.2% - Here's WhyRepligen (NASDAQ:RGEN) Stock Price Down 2.2% - Here's What HappenedOctober 16, 2024 | marketbeat.comRepligen Corp (RGEN) Stock Price Down 4.57% on Oct 16October 16, 2024 | gurufocus.com Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO RGEN Media Mentions By Week RGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGEN News Sentiment▼1.060.46▲Average Medical News Sentiment RGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGEN Articles This Week▼226▲RGEN Articles Average Week Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News CRISPR Therapeutics News Bio-Techne News Denali Therapeutics News Adaptive Biotechnologies News Moderna News Biogen News United Therapeutics News Incyte News Neurocrine Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGEN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
